PD-1/PD-L1 INHIBITORS

The present invention pertains to compounds according to formula (VIII) or a pharmaceutically acceptable salt thereof: (VIII). The invention also pertains to the use of said compounds singly or in combination with additional agents for inhibiting PD-1, PD-Ll and/or the PD-1/PD-L1 interaction or in t...

Full description

Saved in:
Bibliographic Details
Main Authors PHILLIPS, BARTON W, SQUIRES, NEIL H, MEDLEY, JONATHAN WILLIAM, APPLEBY, TODD, JABRI, SALMAN Y, XU, JIE, PARKHILL, ERIC Q, WANG, PEIYUAN, MACHICAO TELLO, PAULO A, AKTOUDIANAKIS, EVANGELOS, WATKINS, WILLIAM J, DU, ZHIMIN, SIMONOVICH, SCOTT PRESTON, METOBO, SAMUEL E, YANG, KIN SHING, VENKATARAMANI, CHANDRASEKAR, NOTTE, GREGORY, GUERRERO, JUAN A, NADUTHAMBI, DEVAN, ZIEBENHAUS, CHRISTOPHER ALLEN, LAD, LATESHKUMAR THAKORLAL, CHO, AESOP, GRAUPE, MICHAEL, MUKHERJEE, PRASENJIT KUMAR
Format Patent
LanguageEnglish
French
Published 25.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention pertains to compounds according to formula (VIII) or a pharmaceutically acceptable salt thereof: (VIII). The invention also pertains to the use of said compounds singly or in combination with additional agents for inhibiting PD-1, PD-Ll and/or the PD-1/PD-L1 interaction or in the treatment of cancer and compositions of said compounds. La présente invention concerne des composés représentés par la formule (VIII) ou un sel acceptable sur le plan pharmaceutique de ceux-ci : L'invention porte également sur l'utilisation de ces composés seuls ou en combinaison avec des agents supplémentaires pour inhiber les récepteurs PD-1, PD-L1 et/ou pour l'interaction des récepteurs PD-1/PD-L1 ou dans le traitement du cancer et des compositions de ces composés.
Bibliography:Application Number: CA20183057864